

References

- (2001). Initial sequencing and analysis of the human genome. *Nature* **409**, 860-921.
- (2005). Nucleophosmin in Acute Myelogenous Leukemia. *New England Journal of Medicine* **352**, 1819-1820.
- (2012). Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. In *Cancer Series*, (ed. A. I. o. H. a. Welfare). Canberra.
- Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D. and Brinster, R. L.** (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* **318**, 533-8.
- Advani, A. S., Lim, K., Gibson, S., Shadman, M., Jin, T., Copelan, E., Kalaycio, M., Sekeres, M. A., Sobecks, R. and Hsi, E.** (2010). OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. *Leuk Lymphoma* **51**, 606-12.
- Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Borresen-Dale, A.-L. et al.** (2013). Signatures of mutational processes in human cancer. *Nature* **500**, 415-421.
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J.** (1990). Basic local alignment search tool. *Journal of molecular biology* **215**, 403-10.
- Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S. M., Kempski, H., Moorman, A. V., Titley, I., Swansbury, J. et al.** (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. *Nature* **469**, 356-361.
- Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, G. Y. and Suda, T.** (2004). Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche. *Cell* **118**, 149-161.
- Au, W. Y., Horsman, D. E., Gascoyne, R. D., Viswanatha, D. S., Klasa, R. J. and Connors, J. M.** (2004). The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases. *Leuk Lymphoma* **45**, 519-528.
- Avet-Loiseau, H.** (2007). Role of genetics in prognostication in myeloma. *Best Pract Res Clin Haematol* **20**, 625-35.
- Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L. et al.** (2007). Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. *Blood* **109**, 3489-95.
- Bade-Döding, C., Göttmann, W., Baigger, A., Farren, M., Lee, K. P., Blasczyk, R. and Huyton, T.** (2014). Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7. *Biochimica et Biophysica Acta (BBA) - General Subjects* **1840**, 1004-1013.
- Bains, A., Luthra, R., Medeiros, L. J. and Zuo, Z.** (2011). FLT3 and NPM1 Mutations in Myelodysplastic Syndromes: Frequency and Potential Value for

Predicting Progression to Acute Myeloid Leukemia. *American Journal of Clinical Pathology* **135**, 62-69.

Banham, A. H., Connors, J. M., Brown, P. J., Cordell, J. L., Ott, G., Sreenivasan, G., Farinha, P., Horsman, D. E. and Gascoyne, R. D. (2005). Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. *Clin Cancer Res* **11**, 1065-72.

Barrans, S. L., Fenton, J. A. L., Banham, A., Owen, R. G. and Jack, A. S. (2004). Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.

Bashford-Rogers, R. J., Palser, A. L., Huntly, B. J., Rance, R., Vassiliou, G. S., Follows, G. A. and Kellam, P. (2013a). Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. *Genome research*.

Bashford-Rogers, R. J., Palser, A. L., Huntly, B. J., Rance, R., Vassiliou, G. S., Follows, G. A. and Kellam, P. (2013b). Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. *Genome Res* **23**, 1874-84.

Baus, J., Liu, L., Heggestad, A. D., Sanz, S. and Fletcher, B. S. (2005). Hyperactive transposase mutants of the Sleeping Beauty transposon. *Mol Ther* **12**, 1148-56.

Beekman, R., Valkhof, M. G., Sanders, M. A., van Strien, P. M. H., Haanstra, J. R., Broeders, L., Geertsma-Kleinekoort, W. M., Veerman, A. J. P., Valk, P. J. M., Verhaak, R. G. et al. (2012). Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. *Blood* **119**, 5071-5077.

Beerman, I., Maloney, W. J., Weissmann, I. L. and Rossi, D. J. (2010). Stem cells and the aging hematopoietic system. *Current Opinion in Immunology* **22**, 500-506.

Ben-Batalla, I., Schultze, A., Wroblewski, M., Erdmann, R., Heuser, M., Waizenegger, J. S., Riecken, K., Binder, M., Schewe, D., Sawall, S. et al. (2013). Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. *Blood* **122**, 2443-2452.

Bereshchenko, O., Mancini, E., Moore, S., Bilbao, D., Månsson, R., Luc, S., Grover, A., Jacobsen, S. E. W., Bryder, D. and Nerlov, C. (2009). Hematopoietic Stem Cell Expansion Precedes the Generation of Committed Myeloid Leukemia-Initiating Cells in C/EBP α Mutant AML. *Cancer Cell* **16**, 390-400.

Bernal-Mizrachi, L., Lovly, C. M. and Ratner, L. (2006). The role of NF- κ B-1 and NF- κ B-2-mediated resistance to apoptosis in lymphomas. *Proceedings of the National Academy of Sciences* **103**, 9220-9225.

Betz, A. G., Milstein, C., Gonzalez-Fernandez, A., Pannell, R., Larson, T. and Neuberger, M. S. (1994). Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. *Cell* **77**, 239-48.

- Bhayat, F., Das-Gupta, E., Smith, C., McKeever, T. and Hubbard, R.** (2009). The incidence of and mortality from leukaemias in the UK: a general population-based study. *BMC Cancer* **9**, 252.
- Bire, S. and Rouleux-Bonnin, F.** (2012). Transposable Elements as Tools for Reshaping the Genome: It Is a Huge World After All! In *Mobile Genetic Elements*, vol. 859 (ed. Y. Bigot), pp. 1-28: Humana Press.
- Birnbaum, R. A., O'Marcaigh, A., Wardak, Z., Zhang, Y.-Y., Dranoff, G., Jacks, T., Clapp, D. W. and Shannon, K. M.** (2000). Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. *Mol Cell* **5**, 189-195.
- Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R. et al.** (2014). Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun* **5**.
- Bonetti, P., Testoni, M., Scandurra, M., Ponzoni, M., Piva, R., Mensah, A. A., Rinaldi, A., Kwee, I., Tibiletti, M. G., Iqbal, J. et al.** (2013). Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. *Blood* **122**, 2233-41.
- Boudry-Labis, E., Roche-Lestienne, C., Nibourel, O., Boissel, N., Terre, C., Perot, C., Eclache, V., Gachard, N., Tigaud, I., Plessis, G. et al.** (2013). Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. *American Journal of Hematology* **88**, 306-311.
- Bradbury, D., Rogers, S., Reilly, I. A., Kozlowski, R. and Russell, N. H.** (1992). Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukaemia cells--studies using purified CD34-positive cells. *Leukemia* **6**, 562-6.
- Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E. and Shannon, K. M.** (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. *Proc Natl Acad Sci U S A* **101**, 597-602.
- Brayton, C. F., Treuting, P. M. and Ward, J. M.** (2012). Pathobiology of Aging Mice and GEM: Background Strains and Experimental Design. *Veterinary Pathology Online* **49**, 85-105.
- Brennan, S. K. and Matsui, W.** (2009). Cancer stem cells: controversies in multiple myeloma. *Journal of Molecular Medicine-Jmm* **87**, 1079-1085.
- Budd, R. C., Yeh, W.-C. and Tschopp, J.** (2006). cFLIP regulation of lymphocyte activation and development. *Nat Rev Immunol* **6**, 196-204.
- Bunda, S., Kang, M. W., Sybingco, S. S., Weng, J., Favre, H., Shin, D. H., Irwin, M. S., Loh, M. L. and Ohh, M.** (2013). Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. *Cancer Res* **73**, 2540-50.
- Busque, L., Patel, J. P., Figueroa, M. E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A. et al.** (2012). Recurrent

somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet* **44**, 1179-1181.

Butzler, C., Zou, X., Popov, A. V. and Bruggemann, M. (1997). Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-mycYAC. *Oncogene* **14**, 1383-8.

Cadinanos, J. and Bradley, A. (2007). Generation of an inducible and optimized piggyBac transposon system. *Nucleic Acids Res* **35**, e87.

Caligiuri, M. A., Briesewitz, R., Yu, J., Wang, L., Wei, M., Arnoczky, K. J., Marburger, T. B., Wen, J., Perrotti, D., Bloomfield, C. D. et al. (2007). Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. *Blood* **110**, 1022-4.

Campbell, P. J., Pleasance, E. D., Stephens, P. J., Dicks, E., Rance, R., Goodhead, I., Follows, G. A., Green, A. R., Futreal, P. A. and Stratton, M. R. (2008). Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. *Proceedings of the National Academy of Sciences* **105**, 13081-13086.

Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L. et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* **467**, 1109-1113.

Carlson, C. M., Dupuy, A. J., Fritz, S., Roberg-Perez, K. J., Fletcher, C. F. and Largaespada, D. A. (2003). Transposon mutagenesis of the mouse germline. *Genetics* **165**, 243-56.

Catlin, S. N., Busque, L., Gale, R. E., Guttorp, P. and Abkowitz, J. L. (2011). The replication rate of human hematopoietic stem cells in vivo. *Blood* **117**, 4460-4466.

Cattoretti, G., Pasqualucci, L., Ballon, G., Tam, W., Nandula, S. V., Shen, Q., Mo, T., Murty, V. V. and Dalla-Favera, R. (2005). Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. *Cancer Cell* **7**, 445-455.

Caudill, J. S. C., Sternberg, A. J., Li, C.-Y., Tefferi, A., Lasho, T. L. and Steensma, D. P. (2006). C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. *British Journal of Haematology* **133**, 638-641.

Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y. et al. (2012). Dnmt3a is essential for hematopoietic stem cell differentiation. *Nat Genet* **44**, 23-31.

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J. P., Ahmann, G. J., Adli, M. et al. (2011). Initial genome sequencing and analysis of multiple myeloma. *Nature* **471**, 467-72.

Cheng, K., Sportoletti, P., Ito, K., Clohessy, J. G., Teruya-Feldstein, J., Kutok, J. L. and Pandolfi, P. P. (2010). The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. *Blood* **115**, 3341-3345.

Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K. et al. (2008). AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. *Cancer Cell* **13**, 167-80.

- Chng, W. J., Glebov, O., Bergsagel, P. L. and Kuehl, W. M.** (2007). Genetic events in the pathogenesis of multiple myeloma. *Best Pract Res Clin Haematol* **20**, 571-96.
- Chng, W. J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S. V., Oken, M. M., Kyle, R. A., Henderson, K. J., Van Wier, S., Greipp, P. et al.** (2008). Clinical and biological significance of RAS mutations in multiple myeloma. *Leukemia* **22**, 2280-2284.
- Choo, A., Palladinetti, P., Holmes, T., Basu, S., Shen, S., Lock, R. B., O'Brien, T. A., Symonds, G. and Dolnikov, A.** (2008). siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth. *Int J Oncol* **33**, 175-83.
- Cobaleda, C., Schebesta, A., Delogu, A. and Busslinger, M.** (2007). Pax5: the guardian of B cell identity and function. *Nat Immunol* **8**, 463-470.
- Collier, L. S., Adams, D. J., Hackett, C. S., Bendzick, L. E., Akagi, K., Davies, M. N., Diers, M. D., Rodriguez, F. J., Bender, A. M., Tieu, C. et al.** (2009). Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. *Cancer Res* **69**, 8429-37.
- Collier, L. S., Carlson, C. M., Ravimohan, S., Dupuy, A. J. and Largaespada, D. A.** (2005). Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. *Nature* **436**, 272-6.
- Costello, L. C. and Franklin, R. B.** (2013). A Review of the Current Status and Concept of the Emerging Implications of Zinc and Zinc Transporters in the Development of Pancreatic Cancer. *Pancreat Disord Ther* **4**, 002.
- Costello, L. C., Zou, J., Desouki, M. M. and Franklin, R. B.** (2012). Evidence for changes in RREB-1, ZIP3, and Zinc in the early development of pancreatic adenocarcinoma. *J Gastrointest Cancer* **43**, 570-8.
- Courville, E. L., Wu, Y., Kourda, J., Roth, C. G., Brockmann, J., Muzikansky, A., Fathi, A. T., de Leval, L., Orazi, A. and Hasserjian, R. P.** (2013). Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. *Mod Pathol* **26**, 751-761.
- Cozzio, A., Passegué, E., Ayton, P. M., Karsunky, H., Cleary, M. L. and Weissman, I. L.** (2003). Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. *Genes Dev* **17**, 3029-3035.
- Cutts, B. A., Sjogren, A.-K. M., Andersson, K. M. E., Wahlstrom, A. M., Karlsson, C., Swolin, B. and Bergo, M. O.** (2009). Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. *Blood* **114**, 3629-3632.
- Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C. and Croce, C. M.** (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc Natl Acad Sci U S A* **79**, 7824-7827.
- Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-w., Hopf, C., Savitski, M. M. et al.** (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. *Nature* **478**, 529-533.

- de Ridder, J., Uren, A., Kool, J., Reinders, M. and Wessels, L.** (2006). Detecting Statistically Significant Common Insertion Sites in Retroviral Insertional Mutagenesis Screens. *PLoS Comput Biol* **2**, e166.
- Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A. et al.** (2009). Mutation in TET2 in Myeloid Cancers. *New England Journal of Medicine* **360**, 2289-2301.
- Delker, R. K., Fugmann, S. D. and Papavasiliou, F. N.** (2009). A coming-of-age story: activation-induced cytidine deaminase turns 10. *Nat Immunol* **10**, 1147-53.
- Dent, A. L., Shaffer, A. L., Yu, X., Allman, D. and Staudt, L. M.** (1997). Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6. *Science* **276**, 589-592.
- Devon, R. S., Porteous, D.J, Brookes, A.J.** (1995). Splinkerettes-improved vectorettes for greater efficiency in PCR walking. *Nucleic Acids Res* **23**, 1644-1645.
- Dierlamm, J., Baens, M., Wlodarska, I., Stefanova-Ouzounova, M., Hernandez, J. M., Hossfeld, D. K., De Wolf-Peeters, C., Hagemeijer, A., Van den Berghe, H. and Marynen, P.** (1999). The Apoptosis Inhibitor Gene API2 and a Novel 18q Gene, MLT, Are Recurrently Rearranged in the t(11;18)(q21;q21) Associated With Mucosa-Associated Lymphoid Tissue Lymphomas.
- Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D. et al.** (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature* **481**, 506-510.
- Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y. and Xu, T.** (2005). Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. *Cell* **122**, 473-83.
- Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P. and Grandien, A.** (1999). The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors. *J Exp Med* **190**, 1025-1032.
- Dores, G. M., Devesa, S. S., Curtis, R. E., Linet, M. S. and Morton, L. M.** (2012). Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. *Blood* **119**, 34-43.
- Dufour, A., Schneider, F., Metzeler, K. H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.-C., Berdel, W. E., Büchner, T. et al.** (2010). Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. *Journal of Clinical Oncology* **28**, 570-577.
- Dupuy, A. J., Akagi, K., Largaespada, D. A., Copeland, N. G. and Jenkins, N. A.** (2005). Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. *Nature* **436**, 221-6.
- Dupuy, A. J., Rogers, L. M., Kim, J., Nannapaneni, K., Starr, T. K., Liu, P., Largaespada, D. A., Scheetz, T. E., Jenkins, N. A. and Copeland, N. G.** (2009). A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. *Cancer Res* **69**, 8150-6.

- Erkeland, S. J., Valkhof, M., Heijmans-Antonissen, C., van Hoven-Beijen, A., Delwel, R., Hermans, M. H. and Touw, I. P.** (2004). Large-scale identification of disease genes involved in acute myeloid leukemia. *J Virol* **78**, 1971-80.
- Evan, G. I., Lewis, G. K., Ramsay, G. and Bishop, J. M.** (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol Cell Biol* **5**, 3610-6.
- Falini, B., Bolli, N., Shan, J., Martelli, M. P., Liso, A., Pucciarini, A., Bigerna, B., Pasqualucci, L., Mannucci, R., Rosati, R. et al.** (2006). Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood* **107**, 4514-4523.
- Falini, B., Martelli, M. P., Bolli, N., Sportoletti, P., Liso, A., Tiacci, E. and Haferlach, T.** (2011). Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? *Blood* **117**, 1109-1120.
- Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A. et al.** (2005). Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. *New England Journal of Medicine* **352**, 254-266.
- Ferch, U., Kloo, B., Gewies, A., Pfänder, V., Düwel, M., Peschel, C., Krappmann, D. and Ruland, J.** (2009). Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. *J Exp Med* **206**, 2313-2320.
- Fernandez-Mercado, M., Yip, B. H., Pellagatti, A., Davies, C., Larrayoz, M. J., Kondo, T., Pérez, C., Killick, S., McDonald, E.-J., Odero, M. D. et al.** (2012). Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics. *Plos One* **7**, e42334.
- Figuroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F. et al.** (2010). Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. *Cancer Cell* **18**, 553-567.
- Ford, A. M., Ridge, S. A., Cabrera, M. E., Mahmoud, H., Steel, C. M., Chan, L. C. and Greaves, M.** (1993). In utero rearrangements in the trithorax-related oncogene in infant leukaemias. *Nature* **363**, 358-360.
- Forsberg, Lars A., Rasi, C., Razzaghian, Hamid R., Pakalapati, G., Waite, L., Thilbeault, Krista S., Ronowicz, A., Wineinger, Nathan E., Tiwari, Hemant K., Boomsma, D. et al.** (2012). Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. *The American Journal of Human Genetics* **90**, 217-228.
- Friedel, R. H., Friedel, C. C., Bonfert, T., Shi, R., Rad, R. and Soriano, P.** (2013). Clonal Expansion Analysis of Transposon Insertions by High-Throughput Sequencing Identifies Candidate Cancer Genes in a PiggyBac Mutagenesis Screen. *Plos One* **8**, e72338.
- Fujiwara, T., Fukuhara, N., Funayama, R., Nariai, N., Kamata, M., Nagashima, T., Kojima, K., Onishi, Y., Sasahara, Y., Ishizawa, K. et al.** (2014). Identification of

acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia. *Ann Hematol*, 1-8.

Gaidzik, V. I., Paschka, P., Späth, D., Habdank, M., Köhne, C.-H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.-A., Haase, D. et al. (2012). TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group. *Journal of Clinical Oncology* **30**, 1350-1357.

Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K. and Linch, D. C. (2008). The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. *Blood* **111**, 2776-2784.

Gamis, A. S., Alonzo, T. A., Gerbing, R. B., Hilden, J. M., Sorrell, A. D., Sharma, M., Loew, T. W., Arceci, R. J., Barnard, D., Doyle, J. et al. (2011). Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. *Blood* **118**, 6752-6759.

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P. et al. (2012). Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. *New England Journal of Medicine* **366**, 883-892.

Geurts, A. M., Yang, Y., Clark, K. J., Liu, G., Cui, Z., Dupuy, A. J., Bell, J. B., Largaespada, D. A. and Hackett, P. B. (2003). Gene transfer into genomes of human cells by the sleeping beauty transposon system. *Mol Ther* **8**, 108-17.

Gilliland, D. G. and Griffin, J. D. (2002). The roles of FLT3 in hematopoiesis and leukemia. *Blood* **100**, 1532-1542.

Goatly, A., Bacon, C. M., Nakamura, S., Ye, H., Kim, I., Brown, P. J., Ruskone-Fourmesttraux, A., Cervera, P., Streubel, B., Banham, A. H. et al. (2008). FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. *Mod Pathol* **21**, 902-911.

Gough, S. M., Slape, C. I. and Aplan, P. D. (2011). NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. *Blood* **118**, 6247-6257.

Greaves, M. and Maley, C. C. (2012). Clonal evolution in cancer. *Nature* **481**, 306-313.

Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C. and Gale, R. E. (2010). Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. *Journal of Clinical Oncology* **28**, 2739-2747.

Grisendi, S., Mecucci, C., Falini, B. and Pandolfi, P. P. (2006). Nucleophosmin and cancer. *Nat Rev Cancer* **6**, 493-505.

Grove, C. S. and Vassiliou, G. S. (2014). Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? *Disease Models & Mechanisms* **7**, 941-951.

- Gruber, Tanja A., Larson Gedman, A., Zhang, J., Koss, Cary S., Marada, S., Ta, Huy Q., Chen, S.-C., Su, X., Ogden, Stacey K., Dang, J. et al.** (2012). An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. *Cancer Cell* **22**, 683-697.
- Haferlach, C., Dicker, F., Kohlmann, A., Schindela, S., Weiss, T., Kern, W., Schnittger, S. and Haferlach, T.** (2010). AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. *Leukemia* **24**, 1065-1069.
- Haferlach, C., Grossmann, V., Kohlmann, A., Schindela, S., Kern, W., Schnittger, S. and Haferlach, T.** (2012). Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases. *Leukemia* **26**, 834-839.
- Han, S., Dillon, S. R., Zheng, B., Shimoda, M., Schlissel, M. S. and Kelsoe, G.** (1997). V(D)J Recombinase Activity in a Subset of Germinal Center B Lymphocytes. *Science* **278**, 301-305.
- Hanahan, D. and Weinberg, R. A.** (2000). The Hallmarks of Cancer. *Cell* **100**, 57-70.
- Hardy, R. R. and Hayakawa, K.** (2001). B cell development pathways. *Annu Rev Immunol* **19**, 595-621.
- Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L. and Adams, J. M.** (1988). The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. *J Exp Med* **167**, 353-371.
- Harris, J., Ibrahim, H., Amen, F., Karadimitris, A., Naresh, K. N. and Macdonald, D. H.** (2012). Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. *Hematological Oncology* **30**, 8-12.
- He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J. et al.** (2005). A microRNA polycistron as a potential human oncogene. *Nature* **435**, 828-833.
- Horie, K., Yusa, K., Yae, K., Odajima, J., Fischer, S. E., Keng, V. W., Hayakawa, T., Mizuno, S., Kondoh, G., Ijiri, T. et al.** (2003). Characterization of Sleeping Beauty transposition and its application to genetic screening in mice. *Mol Cell Biol* **23**, 9189-207.
- Hou, Y., Song, L., Zhu, P., Zhang, B., Tao, Y., Xu, X., Li, F., Wu, K., Liang, J., Shao, D. et al.** (2012). Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm. *Cell* **148**, 873-885.
- Huff, C. A. and Matsui, W.** (2008). Multiple myeloma cancer stem cells. *Journal of Clinical Oncology* **26**, 2895-2900.
- Huntly, B. J. P., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I. R. et al.** (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. *Cancer Cell* **6**, 587-596.

- Ichikawa, S., Fukuhara, N., Katsushima, H., Takahashi, T., Yamamoto, J., Yokoyama, H., Sasaki, O., Fukuhara, O., Nomura, J., Ishizawa, K. et al. (2014).** Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma. *Cancer Science* **105**, 437-444.
- Iqbal, J., Greiner, T. C., Patel, K., Dave, B. J., Smith, L., Ji, J., Wright, G., Sanger, W. G., Pickering, D. L., Jain, S. et al. (2007).** Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. *Leukemia* **21**, 2332-2343.
- Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O. et al. (2013a).** Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. *Journal of Clinical Oncology* **31**, 2428-2436.
- Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Adès, L., Fenaux, P., Platzbecker, U., Gagey, O. et al. (2013b).** Clonal architecture of chronic myelomonocytic leukemias. *Blood* **121**, 2186-2198.
- Itzykson, R. and Solary, E. (2013).** An evolutionary perspective on chronic myelomonocytic leukemia. *Leukemia*.
- Ivics, Z., Hackett, P. B., Plasterk, R. H. and Izsvák, Z. (1997).** Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells. *Cell* **91**, 501-510.
- Ivics, Z., Li, M. A., Mates, L., Boeke, J. D., Nagy, A., Bradley, A. and Izsvak, Z. (2009).** Transposon-mediated genome manipulation in vertebrates. *Nat Meth* **6**, 415-422.
- Izsvák, Z., Ivics, Z. and Plasterk, R. H. (2000).** Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. *Journal of Molecular Biology* **302**, 93-102.
- Izsvák, Z., Khare, D., Behlke, J., Heinemann, U., Plasterk, R. H. and Ivics, Z. (2002).** Involvement of a Bifunctional, Paired-like DNA-binding Domain and a Transpositional Enhancer in Sleeping Beauty Transposition. *Journal of Biological Chemistry* **277**, 34581-34588.
- Jacobs, K. B., Yeager, M., Zhou, W., Wacholder, S., Wang, Z., Rodriguez-Santiago, B., Hutchinson, A., Deng, X., Liu, C., Horner, M.-J. et al. (2012).** Detectable clonal mosaicism and its relationship to aging and cancer. *Nat Genet* **44**, 651-658.
- Jacobson, J. W., Medhora, M. M. and Hartl, D. L. (1986).** Molecular structure of a somatically unstable transposable element in *Drosophila*. *Proceedings of the National Academy of Sciences* **83**, 8684-8688.
- Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R. and Majeti, R. (2012).** Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia. *Science Translational Medicine* **4**, 149ra118.
- Jankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C. et al. (2011).** Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. *Blood* **118**, 3932-3941.

- Janz, S. M. I., H.C. Teitell, M.A.** (2008). Mouse Models of Human Mature B Cell and Plasma Cell Neoplasms. *Mouse Models of Human Blood Cancers*.
- Javadi, M., Richmond, T. D., Huang, K. and Barber, D. L.** (2013). CBL Linker Region and RING Finger Mutations Lead to Enhanced Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Signaling via Elevated Levels of JAK2 and LYN. *Journal of Biological Chemistry* **288**, 19459-19470.
- Jemal, A., Siegel, R., Xu, J. and Ward, E.** Cancer statistics, 2010. *CA Cancer J Clin* **60**, 277-300.
- Johnson, G. R., Gonda, T. J., Metcalf, D., Kariharan, I. K. and Cory, S.** (1989). A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor. *EMBO Journal* **8**, 441-448.
- Kanungo, A., Medeiros, L. J., Abruzzo, L. V. and Lin, P.** (2005). Lymphoid neoplasms associated with concurrent t(14;18) and 8q24//c-MYC translocation generally have a poor prognosis. *Mod Pathol* **19**, 25-33.
- Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J. and Gilliland, D. G.** (2002). PML/RAR α and FLT3-ITD induce an APL-like disease in a mouse model. *Proceedings of the National Academy of Sciences* **99**, 8283-8288.
- Kent, O. A., Chivukula, R. R., Mullendore, M., Wentzel, E. A., Feldmann, G., Lee, K. H., Liu, S., Leach, S. D., Maitra, A. and Mendell, J. T.** (2010). Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. *Genes Dev* **24**, 2754-9.
- Kent, O. A., Fox-Talbot, K. and Halushka, M. K.** (2013). RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. *Oncogene* **32**, 2576-85.
- Kihara, R., Nagata, Y., Kiyoi, H., Kato, T., Yamamoto, E., Suzuki, K., Chen, F., Asou, N., Ohtake, S., Miyawaki, S. et al.** (2014). Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. *Leukemia*.
- Klijn, C., Koudijs, M. J., Kool, J., ten Hoeve, J., Boer, M., de Moes, J., Akhtar, W., van Miltenburg, M., Vendel-Zwaagstra, A., Reinders, M. J. et al.** (2013). Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors. *Plos One* **8**.
- Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R. et al.** (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature* **468**, 839-843.
- Kon, A., Shih, L.-Y., Minamino, M., Sanada, M., Shiraishi, Y., Nagata, Y., Yoshida, K., Okuno, Y., Bando, M., Nakato, R. et al.** (2013). Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet* **45**, 1232-1237.
- Kool, J., Uren, A. G., Martins, C. P., Sie, D., de Ridder, J., Turner, G., van Uitert, M., Matentzoglou, K., Lagcher, W., Krimpenfort, P. et al.** Insertional mutagenesis in

mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. *Cancer Res* **70**, 520-31.

Koudijs, M. J., Klijn, C., van der Weyden, L., Kool, J., ten Hoeve, J., Sie, D., Prasetyanti, P. R., Schut, E., Kas, S., Whipp, T. et al. (2011). High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. *Genome Research* **21**, 2181-2189.

Kovalchuk, A. L., Qi, C. F., Torrey, T. A., Taddesse-Heath, L., Feigenbaum, L., Park, S. S., Gerbitz, A., Klobeck, G., Hoertnagel, K., Polack, A. et al. (2000). Burkitt lymphoma in the mouse. *J Exp Med* **192**, 1183-90.

Krönke, J., Bullinger, L., Teleanu, V., Tschürtz, F., Gaidzik, V. I., Kühn, M. W. M., Rücker, F. G., Holzmann, K., Paschka, P., Kapp-Schwörer, S. et al. (2013). Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia. *Blood*.

Kuhn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995). Inducible gene targeting in mice. *Science* **269**, 1427-9.

Küppers, R., Klein, U., Hansmann, M.-L. and Rajewsky, K. (1999). Cellular Origin of Human B-Cell Lymphomas. *New England Journal of Medicine* **341**, 1520-1529.

Kusec, R., Laczika, K., Knöbl, P., Friedl, J., Greinix, H., Kahls, P., Linkesch, W., Schwarzingler, I., Mitterbauer, G. and Purtscher, B. (1994). AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. *Leukemia* **8**, 735-739.

Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A. and Melton, L. J., 3rd. (2006). Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med* **354**, 1362-9.

Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F. and Melton, L. J., 3rd. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* **346**, 564-9.

Lang, R. A., Metcalf, D., Cuthbertson, R. A., Lyons, I., Stanley, E., Kelso, A., Kannourakis, G., Williamson, D. J., Klintworth, G. K., Gonda, T. J. et al. (1987). Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. *Cell* **51**, 675-686.

Langridge, G. C., Phan, M.-D., Turner, D. J., Perkins, T. T., Parts, L., Haase, J., Charles, I., Maskell, D. J., Peters, S. E., Dougan, G. et al. (2009). Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. *Genome Research* **19**, 2308-2316.

Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A. and Dick, J. E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* **367**, 645-648.

Larsson, L. G. and Henriksson, M. A. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. *Exp Cell Res* **316**, 1429-37.

- Lauchle, J. O., Kim, D., Le, D. T., Akagi, K., Crone, M., Krisman, K., Warner, K., Bonifas, J. M., Li, Q., Coakley, K. M. et al.** (2009). Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. *Nature* **461**, 411-4.
- Laurie, C. C., Laurie, C. A., Rice, K., Doheny, K. F., Zelnick, L. R., McHugh, C. P., Ling, H., Hetrick, K. N., Pugh, E. W., Amos, C. et al.** (2012). Detectable clonal mosaicism from birth to old age and its relationship to cancer. *Nat Genet* **44**, 642-650.
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A. et al.** (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **499**, 214-218.
- Le, D. T., Kong, N., Zhu, Y., Lauchle, J. O., Aiyigari, A., Braun, B. S., Wang, E., Kogan, S. C., Le Beau, M. M., Parada, L. et al.** (2004). Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. *Blood* **103**, 4243-4250.
- Lefranc, M. P., Giudicelli, V., Ginestoux, C., Jabado-Michaloud, J., Folch, G., Bellahcene, F., Wu, Y., Gemrot, E., Brochet, X., Lane, J. et al.** (2009). IMGT, the international ImMunoGeneTics information system. *Nucleic acids research* **37**, D1006-12.
- Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J. et al.** (2010). DNMT3A Mutations in Acute Myeloid Leukemia. *New England Journal of Medicine* **363**, 2424-2433.
- Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M. et al.** (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* **456**, 66-72.
- Li, H. and Durbin, R.** (2010). Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **26**, 589-95.
- Li, J., Shen, H., Himmel, K. L., Dupuy, A. J., Largaespada, D. A., Nakamura, T., Shaughnessy, J. D., Jr., Jenkins, N. A. and Copeland, N. G.** (1999). Leukaemia disease genes: large-scale cloning and pathway predictions. *Nat Genet* **23**, 348-53.
- Li, J., Spensberger, D., Ahn, J. S., Anand, S., Beer, P. A., Ghevaert, C., Chen, E., Forrai, A., Scott, L. M., Ferreira, R. et al.** (2010). JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. *Blood* **116**, 1528-1538.
- Li, L. and Clevers, H.** (2010). Coexistence of Quiescent and Active Adult Stem Cells in Mammals. *Science* **327**, 542-545.
- Li, M. A., Pettitt, S. J., Eckert, S., Ning, Z., Rice, S., Cadiñanos, J., Yusa, K., Conte, N. and Bradley, A.** (2013). The piggyBac Transposon Displays Local and Distant Reintegration Preferences and Can Cause Mutations at Noncanonical Integration Sites. *Mol Cell Biol* **33**, 1317-1330.
- Li, Q., Haigis, K. M., McDaniel, A., Harding-Theobald, E., Kogan, S. C., Akagi, K., Wong, J. C. Y., Braun, B. S., Wolff, L., Jacks, T. et al.** (2011). Hematopoiesis

and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. *Blood* **117**, 2022-2032.

Liang, Q., Kong, J., Stalker, J. and Bradley, A. (2009). Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons. *Genesis* **47**, 404-8.

Liu, G., Aronovich, E. L., Cui, Z., Whitley, C. B. and Hackett, P. B. (2004). Excision of Sleeping Beauty transposons: parameters and applications to gene therapy. *The Journal of Gene Medicine* **6**, 574-583.

Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N. E., Greipp, P., Kyle, R. A., Oken, M. M. and Van Ness, B. (1996). Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. *Blood* **88**, 2699-706.

Lo Coco, F., Ye, B. H., Lista, F., Corradini, P., Offit, K., Knowles, D. M., Chaganti, R. S. and Dalla-Favera, R. (1994). Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. *Blood* **83**, 1757-9.

Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., Cheng, J. W., Lee, C. M., Stokoe, D., Bonifas, J. M. et al. (2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. *Blood* **103**, 2325-2331.

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L. et al. (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proceedings of the National Academy of Sciences* **109**, 3879-3884.

Lulli, V., Romania, P., Riccioni, R., Boe, A., Lo-Coco, F., Testa, U. and Marziali, G. (2010). Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiation. *Haematologica* **95**, 1633-1641.

Luo, G., Ivics, Z., Izsvák, Z. and Bradley, A. (1998). Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. *Proceedings of the National Academy of Sciences* **95**, 10769-10773.

MacLennan, I. C., Toellner, K. M., Cunningham, A. F., Serre, K., Sze, D. M., Zuniga, E., Cook, M. C. and Vinuesa, C. G. (2003). Extrafollicular antibody responses. *Immunol Rev* **194**, 8-18.

Malinge, S., Chlon, T., Doré, L. C., Ketterling, R. P., Tallman, M. S., Paietta, E., Gamis, A. S., Taub, J. W., Chou, S. T., Weiss, M. J. et al. (2013). Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. *Blood* **122**, e33-e43.

Malinge, S., Izraeli, S. and Crispino, J. D. (2009). Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. *Blood* **113**, 2619-2628.

Mann, K. M., Jenkins, N. A., Copeland, N. G. and Mann, M. B. (2014). Transposon Insertional Mutagenesis Models of Cancer. *Cold Spring Harbor Protocols* **2014**, pdb.top069849.

Mann, K. M., Ward, J. M., Yew, C. C. K., Kovoichich, A., Dawson, D. W., Black, M. A., Brett, B. T., Sheetz, T. E., Dupuy, A. J., Initiative, A. P. C. G. et al. (2012).

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. *Proceedings of the National Academy of Sciences* **109**, 5934-5941.

March, H. N., Rust, A. G., Wright, N. A., ten Hoeve, J., de Ridder, J., Eldridge, M., van der Weyden, L., Berns, A., Gadiot, J., Uren, A. et al. (2011). Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. *Nat Genet* **43**, 1202-1209.

Mates, L., Chuah, M. K. L., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, A., Grzela, D. P., Schmitt, A., Becker, K., Matrai, J. et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. *Nat Genet* **41**, 753-761.

Maul, R. W. and Gearhart, P. J. AID and somatic hypermutation. *Adv Immunol* **105**, 159-91.

McAllister-Lucas, L. M., Baens, M. and Lucas, P. C. (2011). MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond? *Clinical Cancer Research* **17**, 6623-6631.

McClintock, B. (1950). The origin and behavior of mutable loci in maize. *Proceedings of the National Academy of Sciences* **36**, 344-355.

McKenzie, J. L., Gan, O. I., Doedens, M., Wang, J. C. Y. and Dick, J. E. (2006). Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. *Nat Immunol* **7**, 1225-1233.

Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S. et al. (2012). SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). *Blood* **120**, 3080-3088.

Metcalf, D. (2013). The Colony-Stimulating Factors and Cancer. *Cancer Immunology Research* **1**, 351-356.

Metcalf, D., Glaser, S. P., Xu, Z., Di Rago, L. and Mifsud, S. (2013). Reversible growth factor dependency and autonomy during murine myelomonocytic leukemia induced by oncogenes. *Proceedings of the National Academy of Sciences* **110**, 17029-17034.

Metzeler, K. H., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J., Holland, K. B., Schwind, S., Whitman, S. P. et al. (2011). TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. *Journal of Clinical Oncology* **29**, 1373-1381.

Meyer, N. and Penn, L. Z. (2008). Reflecting on 25 years with MYC. *Nat Rev Cancer* **8**, 976-90.

Milon, B. C., Agyapong, A., Bautista, R., Costello, L. C. and Franklin, R. B. (2010). Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells. *Prostate* **70**, 288-96.

Miyamoto, T., Nagafuji, K., Akashi, K., Harada, M., Kyo, T., Akashi, T., Takenaka, K., Mizuno, S., Gondo, H., Okamura, T. et al. (1996). Persistence of

multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. *Blood* **87**, 4789-4796.

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, Maria E., Vasanthakumar, A., Patel, J., Zhao, X. et al. (2011). Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. *Cancer Cell* **20**, 11-24.

Mori, H., Colman, S. M., Xiao, Z., Ford, A. M., Healy, L. E., Donaldson, C., Hows, J. M., Navarrete, C. and Greaves, M. (2002). Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proceedings of the National Academy of Sciences* **99**, 8242-8247.

Morin, R. D., Mungall, K., Pleasance, E., Mungall, A. J., Goya, R., Huff, R. D., Scott, D. W., Ding, J., Roth, A., Chiu, R. et al. (2013). Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Morse, H. C., Anver, M. R., Fredrickson, T. N., Haines, D. C., Harris, A. W., Harris, N. L., Jaffe, E. S., Kogan, S. C., MacLennan, I. C. M., Pattengale, P. K. et al. (2002). Bethesda proposals for classification of lymphoid neoplasms in mice. *Blood* **100**, 246-258.

Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A. and Downing, J. R. (2008). Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia. *Science* **322**, 1377-1380.

Mullins, C. D., Su, M. Y., Huchtagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D., Vij, R. and Tomasson, M. H. (2013). Germinal Center B-Cells Resist Transformation by *Kras* Independently of Tumor Suppressor *Arf*. *Plos One* **8**, e67941.

Mupo, A., Celani, L., Dovey, O., Cooper, J. L., Grove, C., Rad, R., Sportoletti, P., Falini, B., Bradley, A. and Vassiliou, G. S. (2013). A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. *Leukemia* **27**, 1917-1920.

Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D. et al. (2011). Tumour evolution inferred by single-cell sequencing. *Nature* **472**, 90-94.

Nedergaard, T., Guldborg, P., Ralfkiaer, E. and Zeuthen, J. (1997). A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. *Int J Cancer* **71**, 364-9.

Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J. et al. (2006). A loss-of-function RNA interference screen for molecular targets in cancer. *Nature* **441**, 106-110.

Nik-Zainal, S., Van Loo, P., Wedge, David C., Alexandrov, Ludmil B., Greenman, Christopher D., Lau, King W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M. et al. (2012). The Life History of 21 Breast Cancers. *Cell* **149**, 994-1007.

Nikolaev, S. I., Santoni, F., Vannier, A., Falconnet, E., Giarin, E., Basso, G., Hoischen, A., Veltman, J. A., Groet, J., Nizetic, D. et al. (2013). Exome

sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. *Blood* **122**, 554-561.

Niu, H., Ye, B. H. and Dalla-Favera, R. (1998). Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. *Genes Dev* **12**, 1953-1961.

Notta, F., Mullighan, C. G., Wang, J. C. Y., Poepl, A., Doulatov, S., Phillips, L. A., Ma, J., Minden, M. D., Downing, J. R. and Dick, J. E. (2011). Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. *Nature* **469**, 362-367.

Nowell, P. (1976). The clonal evolution of tumor cell populations. *Science* **194**, 23-28.

Offit, K., Lo Coco, F., Louie, D. C., Parsa, N. Z., Leung, D., Portlock, C., Ye, B. H., Lista, F., Filippa, D. A., Rosenbaum, A. et al. (1994). Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. *N Engl J Med* **331**, 74-80.

Ohno, S., Babonits, M., Wiener, F., Spira, J., Klein, G. and Potter, M. (1979). Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. *Cell* **18**, 1001-1007.

Palomo, C., Zou, X., Nicholson, I. C., Butzler, C. and Bruggemann, M. (1999). B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu). *Cancer Res* **59**, 5625-8.

Palumbo, A. and Rajkumar, S. V. (2009). Treatment of newly diagnosed myeloma. *Leukemia* **23**, 449-56.

Papaemmanuil, E., Cazzola, M., Boulwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C. et al. (2011). Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts. *New England Journal of Medicine* **365**, 1384-1395.

Papaemmanuil, E., Rapado, I., Li, Y., Potter, N. E., Wedge, D. C., Tubio, J., Alexandrov, L. B., Van Loo, P., Cooke, S. L., Marshall, J. et al. (2014). RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. *Nat Genet* **46**, 116-125.

Papavasiliou, F. N. and Schatz, D. G. (2000). Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. *Nature* **408**, 216-21.

Park, S. S., Kim, J. S., Tessarollo, L., Owens, J. D., Peng, L., Han, S. S., Tae Chung, S., Torrey, T. A., Cheung, W. C., Polakiewicz, R. D. et al. (2005). Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. *Cancer Res* **65**, 1306-15.

Parkin, B., Ouillette, P., Li, Y., Keller, J., Lam, C., Roulston, D., Li, C., Shedden, K. and Malek, S. N. (2013). Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. *Blood* **121**, 369-377.

Parkin, B., Ouillette, P., Wang, Y., Liu, Y., Wright, W., Roulston, D., Purkayastha, A., Dressel, A., Karp, J., Bockenstedt, P. et al. (2010). NF1

Inactivation in Adult Acute Myelogenous Leukemia. *Clinical Cancer Research* **16**, 4135-4147.

Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V. A., Grunn, A., Messina, M., Elliot, O. et al. (2011). Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* **43**, 830-837.

Peabody, D. S. (1989). Translation initiation at non-AUG triplets in mammalian cells. *J Biol Chem* **264**, 5031-5.

Pine, S. R., Guo, Q., Yin, C., Jayabose, S., Druschel, C. M. and Sandoval, C. (2007). Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. *Blood* **110**, 2128-2131.

Poppe, B., Vandesompele, J., Schoch, C., Lindvall, C., Mrózek, K., Bloomfield, C. D., Beverloo, H. B., Michaux, L., Dastugue, N., Herens, C. et al. (2004). Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. *Blood* **103**, 229-235.

Prchal, J. T., Prchal, J. F., Belickova, M., Chen, S., Guan, Y., Gartland, G. L. and Cooper, M. D. (1996). Clonal stability of blood cell lineages indicated by X-chromosomal transcriptional polymorphism. *J Exp Med* **183**, 561-567.

Quivoron, C., Couronné, L., Della Valle, V., Lopez, Cécile K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H. et al. (2011). TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. *Cancer Cell* **20**, 25-38.

Rad, R., Rad, L., Wang, W., Cadinanos, J., Vassiliou, G., Rice, S., Campos, L. S., Yusa, K., Banerjee, R., Li, M. A. et al. (2010). PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice. *Science* **330**, 1104-1107.

Rad, R., Rad, L., Wang, W., Cadinanos, J et al. (2010). *PiggyBac* Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice. *Science* **In press**.

Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L. et al. (2008). A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Raval, A., Kusler, B., Pang, W. W., Weissman, I. L., Mitchell, B. S. and Park, C. Y. Effect of nucleophosmin1 haploinsufficiency on hematopoietic stem cells: Leukemia. 2012 Apr;26(4):853-5. doi: 10.1038/leu.2011.270. Epub 2011 Oct 7.

Refaeli, Y., Young, R. M., Turner, B. C., Duda, J., Field, K. A. and Bishop, J. M. (2008). The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. *PLoS Biol* **6**, e152.

Rhoades, K. L., Hetherington, C. J., Harakawa, N., Yergeau, D. A., Zhou, L., Liu, L.-Q., Little, M.-T., Tenen, D. G. and Zhang, D.-E. (2000). Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. *Blood* **96**, 2108-2115.

Riccioni, R., Diverio, D., Riti, V., Buffolino, S., Mariani, G., Boe, A., Cedrone, M., Ottone, T., Foà, R. and Testa, U. (2009). Interleukin (IL)-3/granulocyte

macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. *British Journal of Haematology* **144**, 376-387.

Rogozin, I. B. and Diaz, M. (2004). Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. *J Immunol* **172**, 3382-4.

Rovigatti, U., Watson, D. K. and Yunis, J. J. (1986). Amplification and rearrangement of Hu-ets-1 in leukemia and lymphoma with involvement of 11q23. *Science* **232**, 398-400.

Saito, M., Gao, J., Basso, K., Kitagawa, Y., Smith, P. M., Bhagat, G., Pernis, A., Pasqualucci, L. and Dalla-Favera, R. (2007). A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. *Cancer Cell* **12**, 280-292.

Sakane-Ishikawa, E., Nakatsuka, S., Tomita, Y., Fujita, S., Nakamichi, I., Takakuwa, T., Sugiyama, H., Fukuhara, S., Hino, M., Kanamaru, A. et al. (2005). Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. *J Clin Oncol* **23**, 8012-7.

Sarver, A., Erdman, J., Starr, T., Largaespada, D. and Silverstein, K. A. (2012). TAPDANCE: An automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data. *BMC Bioinformatics* **13**, 154.

Sato, T., Onai, N., Yoshihara, H., Arai, F., Suda, T. and Ohteki, T. (2009). Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. *Nat Med* **15**, 696-700.

Schick, U. M., McDavid, A., Crane, P. K., Weston, N., Ehrlich, K., Newton, K. M., Wallace, R., Bookman, E., Harrison, T., Aragaki, A. et al. (2013). Confirmation of the Reported Association of Clonal Chromosomal Mosaicism with an Increased Risk of Incident Hematologic Cancer. *Plos One* **8**, e59823.

Schnittger, S., Bacher, U., Haferlach, C., Alpermann, T., Dicker, F., Sundermann, J., Kern, W. and Haferlach, T. (2011). Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. *Leukemia* **25**, 615-621.

Schwarz, G. (1978). Estimating the Dimension of a Model. *Annals of Statistics* **6**, 461-464.

Shah, A., Andersson, T. M. L., Racht, B., Björkholm, M. and Lambert, P. C. (2013). Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. *British Journal of Haematology* **162**, 509-516.

Shen-Ong, G. L. C., Keath, E. J., Piccoli, S. P. and Cole, M. D. (1982). Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. *Cell* **31**, 443-452.

Shi, J. and Vakoc, Christopher R. (2014). The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. *Mol Cell* **54**, 728-736.

Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W. et al. (2014). Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. *Nature advance online publication*.

Sportoletti, P., Varasano, E., Rossi, R., Bereshchenko, O., Cecchini, D., Gionfriddo, I., Bolli, N., Tiacchi, E., Intermesoli, T., Zanghi, P. et al. (2013). The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. *Blood* **121**, 3447-3458.

Starck, S. R., Ow, Y., Jiang, V., Tokuyama, M., Rivera, M., Qi, X., Roberts, R. W. and Shastri, N. (2008). A Distinct Translation Initiation Mechanism Generates Cryptic Peptides for Immune Surveillance. *Plos One* **3**, e3460.

Starr, T., Allaei, R., Silverstein, K., Staggs, R., Sarver, A., Bergemann, T., Gupta, M., O'Sullivan, M., Matise, I., Dupuy, A. et al. (2009). A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. *Science* **323**, 1747 - 1750.

Stephen, Andrew G., Esposito, D., Bagni, Rachel K. and McCormick, F. (2014). Dragging Ras Back in the Ring. *Cancer Cell* **25**, 272-281.

Stratton, M. R., Campbell, P. J. and Futreal, P. A. (2009). The cancer genome. *Nature* **458**, 719-724.

Sureban, S. M., May, R., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S. A., Pantazis, P., Rao, C. V., Postier, R. G. et al. (2013). DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. *Plos One* **8**.

Suzuki, T., Kiyoi, H., Ozeki, K., Tomita, A., Yamaji, S., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K. et al. (2005). Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. *Blood* **106**, 2854-61.

Swerdlow, S. H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S. A., Stein, H., Thiele, J., Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: WHO.

Swierczek, S. I., Agarwal, N., Nussenzveig, R. H., Rothstein, G., Wilson, A., Artz, A. and Prchal, J. T. (2008). Hematopoiesis is not clonal in healthy elderly women. *Blood* **112**, 3186-3193.

Szymanska, H., Lechowska-Piskorowska, J., Krysiak, E., Strzalkowska, A., Unrug-Bielawska, K., Grygalewicz, B., Skurzak, H., Pienkowska-Grela, B. and Gajewska, M. (2013). Neoplastic and Nonneoplastic Lesions in Aging Mice of Unique and Common Inbred Strains Contribution to Modeling of Human Neoplastic Diseases. *Vet Pathol* **16**, 16.

Szymczak, A. L., Workman, C. J., Wang, Y., Vignali, K. M., Dilioglou, S., Vanin, E. F. and Vignali, D. A. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat Biotechnol* **22**, 589-94.

Tang, J. Z., Carmichael, C. L., Shi, W., Metcalf, D., Ng, A. P., Hyland, C. D., Jenkins, N. A., Copeland, N. G., Howell, V. M., Zhao, Z. J. et al. (2013). Transposon mutagenesis reveals cooperation of ETS family transcription factors with

signaling pathways in erythro-megakaryocytic leukemia. *Proceedings of the National Academy of Sciences* **110**, 6091-6096.

Tartaglia, M. and Gelb, B. D. (2005). Germ-line and somatic PTPN11 mutations in human disease. *European Journal of Medical Genetics* **48**, 81-96.

Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J. D. and Gelb, B. D. (2003). Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. *Nat Genet* **34**, 148-150.

Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A. et al. (2011). Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood* **117**, 2469-2475.

TCGA_Research_Network. (2013). Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. *New England Journal of Medicine* **368**, 2059-2074.

Thiagalingam, A., De Bustros, A., Borges, M., Jasti, R., Compton, D., Diamond, L., Mabry, M., Ball, D. W., Baylin, S. B. and Nelkin, B. D. (1996). RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. *Mol Cell Biol* **16**, 5335-45.

Thol, F., Bollin, R., Gehlhaar, M., Walter, C., Dugas, M., Suchanek, K. J., Kirchner, A., Huang, L., Chaturvedi, A., Wichmann, M. et al. (2013). Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. *Blood*.

Thomas, R. S., Tymms, M. J., Seth, A., Shannon, M. F. and Kola, I. (1995). ETS1 transactivates the human GM-CSF promoter in Jurkat T cells stimulated with PMA and ionomycin. *Oncogene* **11**, 2135-2143.

Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A. et al. (2011). BRAF Mutations in Hairy-Cell Leukemia. *New England Journal of Medicine* **364**, 2305-2315.

Tuborgh, A., Meyer, C., Marschalek, R., Preiss, B., Hasle, H. and Kjeldsen, E. (2013). Complex three-way translocation involving MLL, ELL, RREB1, and CMAHP genes in an infant with acute myeloid leukemia and t(6;19;11)(p22.2;p13.1;q23.3). *Cytogenet Genome Res* **141**, 7-15.

Uren, A. G., Kool, J., Matentzoglou, K., de Ridder, J., Mattison, J., van Uitert, M., Lagcher, W., Sie, D., Tanger, E., Cox, T. et al. (2008). Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. *Cell* **133**, 727-41.

Uren, A. G., Mikkers, H., Kool, J., van der Weyden, L., Lund, A. H., Wilson, C. H., Rance, R., Jonkers, J., van Lohuizen, M., Berns, A. et al. (2009). A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. *Nat. Protocols* **4**, 789-798.

- Valnet-Rabier, M.-B., Challier, B., Thiebault, S., Angonin, R., Margueritte, G., Mouglin, C., Kantelip, B., Deconinck, E., Cahn, J.-Y. and Fest, T.** (2005). c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. *British Journal of Haematology* **128**, 767-773.
- Van Loo, P., Nordgard, S. H., Lingjaerde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B. et al.** (2010). Allele-specific copy number analysis of tumors. *Proc Natl Acad Sci U S A* **107**, 16910-5.
- Vaqué, J. P., Martínez, N., Batlle-López, A., Pérez, C., Montes-Moreno, S., Sánchez-Beato, M. and Piris, M. A.** (2014). B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. *Haematologica* **99**, 222-231.
- Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J. et al.** (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* **469**, 539-542.
- Vassiliou, G. S., Cooper, J. L., Rad, R., Li, J., Rice, S., Uren, A., Rad, L., Ellis, P., Andrews, R., Banerjee, R. et al.** (2011). Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. *Nat Genet* **43**, 470-475.
- Verhaak, R. G. W., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hagens, W., Uitterlinden, A. G., Erpelink, C. A. J., Delwel, R., Löwenberg, B. et al.** (2005). Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood* **106**, 3747-3754.
- Wagner, S. D., Ahearne, M. and Ferrigno, P. K.** (2011). The role of BCL6 in lymphomas and routes to therapy. *British Journal of Haematology* **152**, 3-12.
- Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R. et al.** (2012). Clonal Architecture of Secondary Acute Myeloid Leukemia. *New England Journal of Medicine* **366**, 1090-1098.
- Wang, W., Lin, C., Lu, D., Ning, Z., Cox, T., Melvin, D., Wang, X., Bradley, A. and Liu, P.** (2008). Chromosomal transposition of PiggyBac in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* **105**, 9290-5.
- Wang, X., Li, Z., Naganuma, A. and Ye, B. H.** (2002). Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. *Proceedings of the National Academy of Sciences* **99**, 15018-15023.
- Wang, Y. X., Zhang, J. H. and Gu, Z. W.** (2009). [Beta-catenin and cyclin D1 mRNA levels in newly diagnosed patients with acute myeloid leukemia and their significance]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* **17**, 304-8.
- Ward, A. F., Braun, B. S. and Shannon, K. M.** (2012). Targeting oncogenic Ras signaling in hematologic malignancies. *Blood* **120**, 3397-3406.
- Ward, J. M.** (2006). Lymphomas and leukemias in mice. *Experimental and Toxicologic Pathology* **57**, 377-381.
- Wartman, L. D., Larson, D. E., Xiang, Z., Ding, L., Chen, K., Lin, L., Cahan, P., Kico, J. M., Welch, J. S., Li, C. et al.** (2011). Sequencing a mouse acute

promyelocytic leukemia genome reveals genetic events relevant for disease progression. *The Journal of Clinical Investigation* **121**, 1445-1455.

Weigert, O. and Weinstock, D. M. (2012). The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. *Blood* **120**, 2553-2561.

Welch, John S., Ley, Timothy J., Link, Daniel C., Miller, Christopher A., Larson, David E., Koboldt, Daniel C., Wartman, Lukas D., Lamprecht, Tamara L., Liu, F., Xia, J. et al. (2012). The Origin and Evolution of Mutations in Acute Myeloid Leukemia. *Cell* **150**, 264-278.

Wells, S. M., Kantor, A. B. and Stall, A. M. (1994). CD43 (S7) expression identifies peripheral B cell subsets. *The Journal of Immunology* **153**, 5503-15.

Wiemels, J. L., Ford, A. M., Van Wering, E. R., Postma, A. and Greaves, M. (1999). Protracted and Variable Latency of Acute Lymphoblastic Leukemia After TEL-AML1 Gene Fusion In Utero: Presented at the American Society of Hematology Meeting, held in Miami Beach, FL, December 4-8, 1998, and published as an abstract in *Blood* 92:68a, 1998 (suppl 1). *Blood* **94**, 1057-1062.

Wiemels, J. L., Xiao, Z., Buffler, P. A., Maia, A. T., Ma, X., Dicks, B. M., Smith, M. T., Zhang, L., Feusner, J., Wiencke, J. et al. (2002). In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. *Blood* **99**, 3801-3805.

Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M. and Delwel, R. (2009). Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood* **113**, 3088-3091.

Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L. and Rajewsky, K. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat Immunol* **9**, 405-14.

Xiao, J., Lee, S. T., Xiao, Y., Ma, X., Houseman, E. A., Hsu, L. I., Roy, R., Wensch, M., de Smith, A. J., Chokkalingam, A. et al. (2014). PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia. *Int J Cancer* **4**, 28759.

Yant, S. R., Huang, Y., Akache, B. and Kay, M. A. (2007). Site-directed transposon integration in human cells. *Nucleic Acids Res* **35**, e50.

Yant, S. R., Park, J., Huang, Y., Mikkelsen, J. G. and Kay, M. A. (2004). Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells. *Mol Cell Biol* **24**, 9239-9247.

Ye, B. H., Cattoretti, G., Shen, Q., Zhang, J., Hawe, N., Waard, R. d., Leung, C., Nouri-Shirazi, M., Orazi, A., Chaganti, R. S. K. et al. (1997). The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. *Nat Genet* **16**, 161-170.

- Ye, K., Schulz, M. H., Long, Q., Apweiler, R. and Ning, Z.** (2009). Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics* **25**, 2865-2871.
- Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato-Otsubo, A., Sanada, M., Park, M.-j., Terui, K., Suzuki, H. et al.** (2013). The landscape of somatic mutations in Down syndrome-related myeloid disorders. *Nat Genet* **45**, 1293-1299.
- Young, D. and Griffin, J.** (1986). Autocrine secretion of GM-CSF in acute myeloblastic leukemia. *Blood* **68**, 1178-1181.
- Yusa, K., Zhou, L., Li, M. A., Bradley, A. and Craig, N. L.** (2011). A hyperactive piggyBac transposase for mammalian applications. *Proc Natl Acad Sci U S A* **108**, 1531-6.
- Zayed, H., Izsvak, Z., Walisko, O. and Ivics, Z.** (2004). Development of Hyperactive Sleeping Beauty Transposon Vectors by Mutational Analysis. *Mol Ther* **9**, 292-304.
- Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A., Dunphy, C., Choi, W., Au, W. Y., Srivastava, G. et al.** (2013). Genetic heterogeneity of diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences* **110**, 1398-1403.
- Zhang, S., Qian, X., Redman, C., Bliskovski, V., Ramsay, E. S., Lowy, D. R. and Mock, B. A.** (2003). p16INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. *Oncogene* **22**, 2285-2295.
- Zhang, Y., Zhang, M., Yang, L. and Xiao, Z.** (2007). NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. *Leukemia Research* **31**, 109-111.
- Zingone, A., Cultraro, C. M., Shin, D. M., Bean, C. M., Morse, H. C., 3rd, Janz, S. and Kuehl, W. M.** Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. *Leukemia* **24**, 1171-8.